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BACKGROUND: Endometriosis is associated with an inﬂammatory response. Hence inﬂiximab, an anti-TNF-a
monoclonal antibody, might relieve pain. METHODS: A randomized placebo-controlled trial was designed with 21
women with severe pain and a rectovaginal nodule of at least 1 cm. After 1 month of observation, three infusions
of inﬂiximab (5 mg/kg) or placebo were given. Surgery was performed 3 months later and follow-up continued for
6 months. The primary end-point was pain (dysmenorrhea, deep dyspareunia and non-menstrual pain) rated at
each visit by the clinician and on a daily basis by the patient who in addition scored pain by visual analog pain
scale and analgesia intake. Secondary end-points included the volume of the endometriotic nodule, pelvic tenderness
and the visual appearance of endometriotic lesions at laparoscopy. RESULTS: Pain severity decreased during the
treatment by 30% in both the placebo (P<0.001) and inﬂiximab groups (P<0.001). However, no effect of inﬂiximab
was observed for any of the outcome measures. After surgery, pain scores decreased in both groups to less than 20% of
the initial value. CONCLUSIONS: Inﬂiximab appears not to affect pain associated with deep endometriosis. Treat-
ment is associated with an important placebo effect. After surgery, pain decreases to less than 20%. Trials registration
number ClinicalTrials.gov: NCT00604864.
Introduction
Endometriosis is associated with pelvic pain, especially if deep
and/or ovarian cystic lesions are present (Koninckx et al.,
1991b, 1994). Whether subtle lesions cause pain is not yet sub-
stantiated. The association of pain and typical endometriosis
was derived from observational studies in which women with
pelvic pain have a higher incidence of endometriosis (range:
40–80%) than women with infertility without pain (20–
50%) orcontrolgroups (5–20%) (Koninckx et al., 1991b). Sur-
gical ablation of typical endometriosis has been reported to
decrease pain in several observational studies and in a random-
ized controlled trial (Sutton et al., 1994, 1997; Jacobson et al.,
2001). The strong association between cystic ovarian and deep
endometriosis with severe pelvic pain was invariably noted in
observational studies, and logistic regression showed deep and
cystic endometriosis to be the strongest predictors of pelvic
pain (Koninckx and Martin, 1994; Vercellini et al., 1996). Fol-
lowing the surgical excision, pain invariably decreased by
some 80% (Donnez et al., 1995; Koninckx and Martin, 1997;
Brouwer and Woods, 2007; Darai et al., 2007; Kristensen
and Kjer, 2007).
The pathophysiology of the association between endome-
triosis and pain is poorly understood. Several hypotheses
have been put forward. First, as endometriosis is a hormonally
responsive tissue similar to endometrium, it is reasonable to
assume that mini-menstrual bleedings (Brosens, 1997) cause
pain because of pelvic irritation by blood, by an inﬂammatory
reaction or by the tension in the micro cysts of the lesions. This
hypothesis is supported by a series of observations. During
menstruation pain typically worsens and deep lesions feel
tender (Koninckx et al., 1996a). At laparoscopy, endometriotic
lesions were observed to bleed during menstruation (personal
observation). Natural menopause and all medical treatments,
which inactivate the endometrium (Vercellini et al., 1997,
2007a), prevent menstruation or decrease menstrual blood
loss, including GnRH agonists (Shaw, 1991) and oral contra-
ceptives decrease pain. Inﬂammatory reaction and neo angio-
genesis (Oosterlynck et al., 1993) around endometriotic
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ogy. Secondly, in deep lesions, the observed endometriotic
invasion of nerve ﬁbers and the association with mast cells
(Anaf et al., 2000, 2002, 2004, 2006) might explain the
severe pain. Finally, especially deep endometriosis can cause
sclerotic compression of ureters and of nerve ﬁbers, as demon-
strated by the excision of endometriosis surrounding the sciatic
nerve (Batt et al., 2004; Possover and Chiantera, 2007) or the
pudendal nerve in cases of menstrual sciatalgia or Alcock syn-
drome (Robert et al., 1998; Possover and Chiantera, 2007).
TNF-a, a pro-inﬂammatory cytokine, has been implicated in
the pathophysiology of endometriosis (Agic et al., 2006).
TNF-a levels are increased in peritoneal ﬂuid of women with
endometriosis (Bedaiwy et al., 2002), and the levels correlate
with severity of disease (Richter et al., 2005). Peritoneal
ﬂuid TNF-a is produced locally by activated peritoneal macro-
phages (Koninckx et al., 1999). TNF-a induces IL-8 secretion
by peritoneal mesothelial cells (Arici, 2002). The peritoneal
ﬂuid concentrations of TNF-a and IL-8 correlate with the
size and the number of active peritoneal lesions (Bullimore,
2003). Serum TNF-a levels are increased, and monocytes
from patients with endometriosis release more TNF-a
in vitro compared with monocytes from controls (Braun et al.,
1996). Peritoneal ﬂuid levels of MCP-1 are increased in
patients with endometriosis. TNF-a, IL-8 and MCP-1 drive
an inﬂammatory Th-1 type response in the peritoneal ﬂuid of
patients with endometriosis (Akoum et al., 1995).
The anti-inﬂammatory effect of blocking TNF-a by mono-
clonal antibodies (e.g. inﬂiximab) or by soluble TNF-a recep-
tors (e.g. etanercept) has been demonstrated in vivo in animal
models and also in the human. The clinical effectiveness of
blocking TNF-a has been demonstrated in inﬂammation
driven conditions including Crohn’s disease and rheumatoid
arthritis but not in severe endometriosis (Shakiba and
Falcone, 2006). In baboons with laparoscopically conﬁrmed
endometriosis, TNF-a blockade with p55 soluble TNF-a
receptors results in inhibition of the development and growth
of endometriotic implants (D’Hooghe et al., 2006). The size
of peritoneal red lesions was decreased in comparison with a
control group (Barrier et al., 2004), but there was no increase
in pregnancy rates (Falconer et al., 2007). In rats with ectopi-
cally transplanted endometrial tissue, the administration of
recombinant human TNF-a binding protein-1 (r-hTBP-1)
resulted in defective development of implants compared with
controls (D’Antonio et al., 2000).
TNF-a mediated inﬂammation may be a causal factor in the
pain associated with endometriosis and blocking TNF-a
appears to inhibit the development of the disease in animal
models. We evaluated the effect of inﬂiximab on pain in




All patients (aged 18–50 years) were recruited from a single, tertiary
referral hospital at Leuven University, Belgium. All women suffered
from pelvic pain and were scheduled for surgical excision of a recto-
vaginal endometriotic nodule of at least 1 cm in diameter with or
without cystic ovarian endometriosis. None of the women had pre-
viously been operated for deep endometriosis. All women had a
regular cycle (25–40 days) and moderate to severe pelvic pain as
deﬁned by their score on the Biberoglu–Behrman scale. If previously
treated with hormonal medication, including progestagens, GnRH
analogs, Danazol or oral contraceptives, at least 3 months had
elapsedand theyhadat least two menstrual cycles since stopping treat-
ment. The study was reviewed and approved by the institutional
review board of KULeuven. Written informed consent was obtained
from each subject.
If not sterilized the patient had to agree to use a double-barrier
method of contraception for the duration of the study, and up to 6
months after receiving the last infusion with inﬂiximab.
In view of inﬂiximab’s known side-effect proﬁle, the following
were exclusion criteria: (i) old or currently active TB; (ii) evidence
of serious infections in the previous 3 months; (iii) documented HIV
infection, active hepatitis-B or C, or an opportunistic infection (e.g.
herpes zoster, cytomegalovirus, pneumocystis carinii, aspergillosis,
histoplasmosis or mycobacteria other than TB) in the previous 6
months; (iv) previous transplant surgery, a lymphoproliferative dis-
order or other malignancy; (v) positive cervical cytology in the pre-
vious 6 months; (vi) previous treatment with inﬂiximab or, any drug
known to affect TNF-a levels, e.g. pentoxifylline, thalidomide and
etanercept, or any human/murine recombinant products; (vii)
known allergy to murine products; (viii) recent use of other investiga-
tional drugs within 1 month of recruitment or within ﬁve half-lives of
the investigational agent, whichever was longer and (ix) any hemato-
logical or biochemical abnormalities on routine screening. Subjects
were also excluded if there was pelvic pathology on transvaginal ultra-
sound (TVU) scan other than small uterine ﬁbroids (,4 cm in diam-
eter) or an ovarian endometrioma or endometriotic nodule.
Study design
This study was a single center, randomized, double-blind, placebo-
controlledpilotstudyin21womenwithdeependometriosis-associated
pain in whom excisional surgery was planned as therapy. Randomiz-
ation was performed in a 2–1 ratio for active and placebo treatments,
respectively, 14 women thus receiving active treatment and seven
receiving placebo. In one patient of the inﬂiximab group, with a deep
nodule diagnosed by TVU only, no deep endometriotic nodule was
found during surgery. Both groups were similar for age, weight,
height, blood pressure, heart rate, days of bleeding, age of menarche,
number of pregnancies and spontaneous abortions, leucocyte and
blood cell count and liver function tests. Patients receiving placebo
(n ¼ 7) and inﬂiximab (n ¼ 13) were 30.7+5.5 and 28.4+4.5
years old with a weight of 52.7 þ 5.4 and 62.5+7.4 kg (P ¼ 0.002),
a height of 161 þ 5 and 162 þ 5 cm, a cycle length of 29 þ 2 and
32 þ 5 days, a systolic blood pressure of 127+15 and 120+12 mm
of mercury, a diastolic blood pressure of 78+11 and 78+7m mo f
mercury and a heart rate of 79+14 and 83+12, respectively.
The study period consisted of 40 weeks, i.e. at least 4 weeks pre-
treatment evaluation, a 12 week treatment period followed by
surgery and 24 weeks follow-up period. Visits were scheduled at
least 4 weeks before the start of treatment (Visit 1, Week 4), at the
start of treatment (Visit 2, Week 0), then 2 (Visit 3), 4 (Visit 4), 8
(Visit 5) and 12 (Visit 6) weeks after the start of treatment and 6
(Visit 7) and 12 (Visit 8) weeks after surgery. Inﬂiximab or placebo
was administered as a slow infusion of 250 ml at the beginning of
the cycle (Week 0 or Visit 2) and repeated after 2 (Visit 3) and 6
weeks (Visit 4) reﬂecting the typical induction treatment scheme of
0, 2 and 6 weeks given in other inﬂammatory pathologies, such as
Crohn’s disease and rheumatoid arthritis. Women were monitored
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formed prior to the infusion and on Week 8.
At each visit and during the follow-up period, safety was monitored
through standard blood tests, vital signs and breast examination.
Adverse events were reviewed by a Safety Monitoring Committee
every 3 months.
The primary end-point was the effect of inﬂiximab treatment upon
pelvic pain including the intake of pain killers. Secondary end-points
included the volume of endometriotic nodules assessed clinically and
on TVU, the macroscopical appearance of endometriotic lesions
during surgery and the extend of endometriosis. The revised American
Fertility (rAFS) classiﬁcation system was not used to score
endometriosis since the severity of deep endometriosis is poorly
reﬂected in the rAFS score.
Clinical evaluations of endometriosis and pain assessment
Pain was assessed by one gynecologist (PK) at each visit using a modi-
ﬁed Biberoglu–Behrman scale, scoring from 0 (no pain) to 3 (severe
pain) dysmenorrhea, deep dyspareunia, chronic pelvic pain, pelvic
tenderness and pelvic induration. In addition the patients indepen-
dently recorded daily dyspareunia, dysmenorrhea and pelvic pain
and the intake of Ibuprofen 100 mg tablets. In addition, they recorded
weekly by visual analog pain scale (VAS), the average maximum tol-
erated pain (i.e. before intake of a pain killer) over the last 7 days. Ibu-
profen was taken as required up to a maximum of 2.4 g/day;
additional pain medication was permitted with documentation.
A TVU was performed during the screening period and at Visits 2,
3, 5 and 6 to measure deep endometriosis volume and endometrial
thickness (Timmerman et al., 2002). Patients recorded daily the
amount of vaginal blood loss.
Treatments, randomization and blinding
Inﬂiximab an IgG monoclonal anti-TNF antibodywas supplied by Cen-
tocor as a lyophilized solid containing 100 mg of inﬂiximab IgG, 0.5 g
of sucrose, 6.1 mg of dibasic sodium phosphate dihydrate, 2.2 mg of
monobasic sodium phosphate monohydrate and 0.5 mg of polysorbate
80 in a 20 ml vial for reconstitution in 10 ml of sterile water for injec-
tion. Theplacebowas suppliedasalyophilizedsolidcontaining0.5 gof
sucrose, 6.1 mg of dibasic sodium phosphate dihydrate, 2.2 mg of
monobasic sodium phosphate monohydrate and 0.5 mg of polysorbate
80 in a 20 ml vial for reconstitution in 10 ml of sterile water. The
vials of inﬂiximab/placebo were supplied by Centocor, stored at 2–
88C and reconstituted immediately before each administration.
All investigators, research nurses and patients were blinded
throughout the study. Randomization (prepared by Centocor Paris)
was performed by consecutive sealed envelopes opened by the phar-
macist prior to the preparation of medication. Randomization code
was broken only after the database had been locked.
Surgery and other procedures
Surgery for endometriosis was performed as reported (Koninckx and
Barlow, 1999) 4–6 weeks after the last inﬂiximab dose. A follow-up
visit was planned 4–9 weeks after surgery (Visit 7) and a ﬁnal visit to
assess safety was performed between 26 and 29 weeks (Visit 8).
During surgery, an endometrial biopsy was taken and subsequently
processed for routine pathology.
Statistics
This study was an exploratory trial, and thus not powered to detect
small differences. An important decrease of pain would have been
detected, since with a SD of 2, a difference in BB score of 3 would
have been detected with a power of 90%. To detect small differences,
e.g. of one point with a power of 80% a RCT of 120 women would
have been necessary.
Statistical analysis was performed with the SAS system (SAS/
STAT users guide, 1988). Wilcoxon Rank sum test was used to evalu-
ate differences of means at each visit for each variable. Since in this
study obviously two possible effects were present simultaneously,
i.e. the effect of Inﬂiximab treatment and the effect of placebo or
surgery, a two-way analysis of variance (proc GLM, general linear
methods) was performed, analysing simultaneously for each end-point
the effect of treatment (control or anti-TNF-a) and the placebo or
surgery effect (the difference between two treatment periods).
Baseline was deﬁned as the mean of Visits 1 and 2, the early treatment
period as the mean of Visits 3 and 4 and the late treatment period as
mean of Visits 5 and 6. For the effect of surgery, baseline, early and
late treatment periods were compared with the post-operative period
(mean of Visits 7 and 8).
Since pain was exacerbated during menstruation, the menstrual
period, deﬁned as the ﬁrst 4 days of the cycle was analysed separately.
A menstrual cycle was deﬁned as starting with the ﬁrst day of bleeding
and lasting for 28 days.
The effect upon pain was evaluated from the 5 BB entries made by
the physician, and the 3 BB entries, the VAS scale and the intake of
ibuprofen and other painkillers recorded by the patients. Analysis of
pain killer intake was done twice: a ﬁrst analysis was done considering
only the ibuprofen intake (the number of tablets of ibuprofen taken); in
a second analysis other painkiller intake was taken into account: if
other painkillers had been taken the number of tablets taken was
added to the number of ibuprofen tablets taken; if other strong pain
killers had been injected, e.g. a morphine product, these injections
were arbitrarily scored as six tablets in order to obtain the total
score. In addition, the effect of treatment upon two calculated total
pain scores combining the individual BB entries and pain killer
intake was calculated. A ﬁrst total pain score consisted of the sum
of dysmenorrhea, deep dyspareunia and pelvic pain (both as assessed
by the clinician and by the patients). In order to take also the ibuprofen
intake into account, a second total pain score was calculated by mul-
tiplying the total daily pain score with the number þ1 (in order to
avoid to multiply by zero) of ibuprofen tablets taken during that day.
Both an intention to treat analysis, considering all 21 patients
included, and an analysis of the 20 women with endometriosis was
performed. Since results were identical only the latter will be given
in the manuscript. Means and SE are given unless indicated otherwise.
For the safety analysis, obviously all 14 women treated with Inﬂixi-
mab were included.
Results are presented as mean þ SE. Spearman correlation was
used for correlation analysis.
Results
These women with endometriosis had very severe pain before
treatment with a total BB score of 12.2 on a scale of 15
(Figs 1 and 2). The baseline BB scorings by the clinician were
calculated as 2.7 þ 0.09 for dysmenorrhea, 2.3 þ 0.19 for deep
dyspareunia, 2.2 þ 0.12 for chronic pain, 2.2 þ 0.14 for pelvic
tenderness, 2.8 þ 0.07 for pelvic induration, with a sum of the
pain scores of 7.1 þ 0.24 and a total BB score of 12.2 þ 0.28.
As shown in Figs 1, 2 and 3, during the 12 week treatment
period a similar exponential decrease in pain of some 25–
30% was observed in both the control and the inﬂiximab
group, compatible with a placebo effect. No statistically sig-
niﬁcant differences between placebo and inﬂiximab treatment
could be identiﬁed. The strong and signiﬁcant placebo effect
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for all pain estimations in this study, i.e. the ﬁve scorings by the
clinician and the calculated total scores (i.e. dysmenorrhea,
deep dyspareunia, chronic pain, pelvic tenderness, the sum of
the 3 BB pain scores and the total BB score) and the pain
recorded in the dairy by the patients (i.e. the 3 BB scores, the
visual analog scales, the pain killer intake and both calculated
total scores, i.e. with or without taking pain killer intake into
Figure 1: Dysmenorrhea, deep dyspareunia and chronic pelvic pain, as assessed by the clinician (upper graphs) and by the patient in her diary,
before treatment, during the 12 week treatment period (shaded area) and after surgery.
Baseline versus early treatment: NS, baseline versus late treatment: .0.003 for all. Baseline and late treatment versus post-surgery: P , 0.001 for
all. Inﬂiximab: NS for all.
Figure 2: Induration, pelvic tenderness and total Biberoglu–Behrman score together with VAS scales as recorded at each visit and weekly by the
patient in her diary, before treatment, during the 12 week treatment period (shaded area) and after surgery.
Baseline versus early treatment, NS; baseline versus late treatment, .0.003 for all except NS for VAS dysmenorrhea. Baseline and late treatment
versus post-surgery: P , 0.001 for all. Inﬂiximab: NS for all.
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treatment period (Visits 3 and 4) but highly signiﬁcant for
the late treatment period (Visits 5 and 6) both by two way
analysis of variance (P , 0.003 to 0.001 for all) and when
the placebo (Wilcoxon, P , 0.001) and the inﬂiximab group
(Wilcoxon, P , 0.001) were analysed separately.
No effect of treatment was found upon the mean diameters of
the nodules as measured by TVU. For the placebo group (n ¼ 7)
and the inﬂiximab group (n ¼ 13), the diameters were 15.2+
4.6 and 13.6+3.2 mm, during Visit 3, 15.1+5.12 and
14.25+3.5 mm, during Visit 5, 13.5+4.9 and 15.6+
3.5 mm and during Visit 6, 13.2 þ 3.4 and 15.1 þ 2.38 mm.
Endometrial thickness was not affected by treatment, being at
baseline and at the end of the treatment period for the inﬂiximab
group 5.2 (range 1.3–18) and 7.8 (1.9–11) mm and for the
placebo group 7.7 (1.8–23) and 8.2 (3–15) mm, respectively.
During surgery, no obvious differences were observed in the
extend of the disease, the macroscopic aspect of endometriosis
(vascularization and sclerosis), the duration of surgery and
bleeding estimates. Routine pathology (FC) also showed no
obvious differences between the two groups.
After surgery, all pain estimates decreased to less than 10%
of the baseline in both groups (Figs 1 and 2), and no differences
were found between the placebo and the inﬂiximab group
(two-way analysis of variance). This decrease of pain after
surgery was highly signiﬁcant (P , 0.001) for all pain esti-
mates at all visits.
During treatment all side-effects were reviewed by the safety
committee. One patient had 2 days after the second inﬂiximab
infusion an acute tonsillitis, which resolved quickly by anti-
biotic treatment. One patient had a mild (inﬂiximab) infusion
reaction during the 3rd infusion. One patient developed an
acute leukemia 4 months after the last inﬂiximab infusion.
Two inﬂiximab patients, who failed to use contraception,
became pregnant 6 and 10 weeks after surgery, respectively;
one miscarried spontaneously at 10 weeks and the other deliv-
ered a healthy baby at term. One inﬂiximab patient had myalgia
for a few days after the second infusion and another inﬂiximab
patient had a bad taste in the mouth for a few days; both events
were considered unrelated to the drug by the safety review
committee. There were no AEs reported in the placebo patients.
A Spearman correlation between all entries of the whole
dataset was performed. We realize that this crude analysis is
strictly incorrect since all entries were used as independent
variables, and that this blind analysis carries the risk of spur-
ious correlations. Since correlations were so strong, some
seem worth mentioning. There was a strong intercorrelation
(P , 0.001 for all) between all pain estimates by the physician
(dysmenorrhea, deep dyspareunea and chronic pain) and by the
patients (dysmenorrhea, deep dyspareunea, chronic pain, VAS
scales and ibuprofen intake), suggesting that pain estimates are
not entirely independent. Over the whole observation period,
the inﬂiximab group had a slightly higher intake of pain
killers (P , 0.01), and higher dysmenorrhea scores (P ,
0.001 for physician assessment, for patient VAS scales and
for patient diary). The volume of the nodule assessed by
TVU correlated with the pelvic induration assessed by the
physician (P ¼ 0.04) but surprisingly not with any of the
pain estimates nor with ibuprofen intake. Unexpected corre-
lations were found between weight and temperature (P ,
0.001), between temperature and dysmenorrhea (P , 0.001)
and deep dyspareunea (P , 0.001), and between pulse rate
and pain estimates (P , 0.001).
Discussion
To the best of our knowledge, this is the ﬁrst randomized,
placebo-controlled trial to assess the effect of an anti-TNF-a
drug in the treatment of deep endometriosis-associated pain.
Women with deep lesions were chosen as the study group for
two reasons. First, these lesions were diagnosed on clinical
examination rather than at laparoscopy and the women partici-
pated in the study while awaiting deﬁnitive surgical treatment.
Second, for deep endometriosis the association between pain
and endometriosis is much stronger than for other disease
types (Koninckx et al., 1991a; Vercellini et al., 2007b).
Women with deep endometriosis have severe pain close to
the maximum on a BB painscale, the painful nodules can be
conﬁrmed by clinical exam and less than 5% is pain free
(Koninckx et al., 1996b). A study of women with typical
lesions only would carry a much higher risk of including
women in whom pain is not caused by the endometriosis. In
typical endometriosis pain is highly variable, is rarely very
severe and 30–50% of women are pain free. Women with
deep endometriosis may thus be a preferred group to evaluate
drug effects on endometriosis-associated pain.
The observed placebo effect was unexpectedly high in these
women, and is consistent with previous reports albeit in women
with less severe pain (Sutton et al., 1994, 1997). Placebo effect
was observed for all pain measures, including tenderness on
pelvic examination. The absence of effect upon pelvic indura-
tion, indirectly conﬁrms that the effect on pain was a placebo
effect and that the clinician remained objective.
The strong placebo effect can be explained by the patient per-
ceptionoftheimportanceofanintravenousinfusionfollowedby
the close observation in hospital for 1 h. In addition, the enthu-
siasm of the researchers who became convinced of the efﬁcacy
of inﬂiximab could have been conveyed to the patients. Indeed,
two-thirds of the patients reported a greater than 50% decrease
in pain, with little effect in the remaining third. Understanding
the mechanisms involved in this important decrease of pain by
more than 50% (Fuente-Fernandez et al., 2006; Pacheco-Lopez
et al., 2006; Beauregard, 2007; Benedetti, 2007; Koshi and
Short, 2007; Lidstone and Stoessl, 2007; Olshansky, 2007)
Figure 3: Ibuprofen intake and total pain calculated from the patient
dairy.
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related pain (Rostkowska-Nadolska, 2007).
The lack of efﬁcacy for inﬂiximab as a treatment for deep
endometriosis-associated pain was unexpected because of the
widely held belief that inﬂammation is a major cause of pain
in endometriosis (Vercellini et al., 2007a). However, the patho-
physiology of the severe pain associated with deep endometrio-
sis may be different from that caused by typical lesions, i.e.
inﬂammation might be more important in superﬁcial peritoneal
endometriosis whereas nerve invasion or compression is more
important in deep lesions (Anaf et al., 2000, 2002, 2004, 2006).
This absence of effect upon pain is consistent with the absence
of effect during surgery or after examination by routine pathol-
ogy. Whether another treatment protocol or a higher dose
would be effective cannot be excluded.
We have scrutinized the literature on the medical treatment
of endometriosis-associated pain. The evidence ofefﬁcacy may
be weak as the blinding in most studies appears inadequate.
Researchers and patients were able to guess whether individ-
uals were randomized to placebo or active treatment if men-
struation was prevented or if there were major side-effects
such as hot ﬂushes, or recognizable physical signs such as
vaginal atrophy. In addition, conclusions are usually based
upon a reduction in the total pain score and all drugs that
abolish menstruation will thus by deﬁnition be effective in
reducing dysmenorrhea. Given the strong correlation between
pain symptoms it remains uncertain whether these treatments
are effective for all pain symptoms associated with endome-
triosis or simply dysmenorrhea alone.
The correlations found should be regarded cautiously since
the study is small, and since some might be spurious. It was sur-
prising not to ﬁnd a correlation between the size of the nodules
measured by TVU and the pain estimates. Second, that dysme-
norrhea correlated negatively with age and age of menarche is
an intriguing observation as are the systematic correlations of
pain estimates with temperature, blood pressure and pulse
rate. That anticipation of a clinical exam could have increased
blood pressure and pulse rate more in women with more severe
pain remains speculative.
When designing this study, we were concerned about the
theoretical possibility of increasing post-operative compli-
cation rates as a result of inﬂiximab’s effect on the immune
system. The existing evidence was reassuring, i.e. there were
no differences in length of hospital stay or surgical compli-
cations between patients with Crohn’s disease who received
inﬂiximab 2 months before surgery (n ¼ 22) or 1 month after
surgery (n ¼ 13) compared with matched controls (Parsi
et al., 2002). Since then, two retrospective studies in patients
with Crohn’s disease have similarly concluded that the use of
inﬂiximab, as well as steroids or immunomodulators, before
abdominal surgery does not increase the risk for post-operative
complications (Colombel et al., 2004; Marchal et al., 2004). In
our study, there were no differences in post-operative compli-
cation rates between the groups.
Given that we only recruited women with deep endometrio-
sis, we accept the possibility that anti-TNF-a treatment might
have an effect on other types of endometriosis, e.g. minimal
disease with a marked inﬂammatory component. However,
we urge caution about conducting a study to evaluate the
effect of anti-TNF-a drugs in such patients. We are not con-
vinced that the potential beneﬁts outweigh the risk of serious
side-effects, the high cost of anti-TNF-a drugs and the
ethical problems associated with not treating minimal disease
surgically at the time of diagnosis.
This study conﬁrmed the effectiveness of surgical excision of
deep endometriosis upon pain (Koninckx and Martin, 1994;
Redwine and Wright, 2001; Wright and Redwine, 2002;
Donnez et al., 2004; Garry, 2004). We do not know to what
extend a placebo effect contributes to the surgical outcome.
In conclusion, inﬂiximab appears to have no important ben-
eﬁcial effect upon pain associated with deep endometriosis. We
observed an overall placebo effect of 25%, which reached over
50% in two-thirds of the women, emphasizing the need for well
conducted, double-blind, randomized, placebo-controlled
studies when evaluating novel treatments for pain. The efﬁcacy
of surgical excision upon pain was conﬁrmed, as was the safety
of inﬂiximab treatment in the pre-operative period.
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